Search

Taruna Arora

from Palo Alto, CA
Age ~54
Get Report
Also known as:
Taruna Arora Khare, Taruna A Khare, Taruna M Khare, Arora Khare Taruna, Khare Taruna Arora, Taruna E
Related to:
Sanjay Khare, 60
Connected to:
Aanchal Arora, 36Aashna Arora, 30Aditi Arora, 53Amrinder S Arora, 49Amritpal S Arora, 55Anju Arora, 51Annu Arora, 45Arvind K Arora, 77Avee Arora, 35Avtar S Arora, 91

Taruna Arora Phones & Addresses

  • Palo Alto, CA
  • Redwood City, CA
  • Newbury Park, CA
  • Simi Valley, CA
  • Rochester, MN

Resumes

Resumes

Taruna Arora Photo 1

Mayo Clinic

View page
Location:
2317 Saint Francis Dr, Palo Alto, CA 94303
Industry:
Biotechnology
Work:
NGM Biopharmaceuticals - South San Francisco since Apr 2012
Heading antibody development and bioanalytical assays
RST Biotechnology LLC since Jan 2012
Owner
Mabs since Jan 2012
Editorial board member
Amgen Inc 2003 - Dec 2011
Principal Scientist , Group leader
Protein Pathways 2002 - 2003
Staff Scientist
Education:
Mayo Graduate School
UCLA
Skills:
Biotechnology
Assay Development
Immunology
Drug Development
Protein Chemistry
Drug Discovery
Life Sciences
Clinical Development
Cross Functional Team Leadership
Cro
Bioanalysis
Biochemistry
Oncology
Cell Culture
Fda
Ind
Immunogenicity Models Development
Interests:
Disaster and Humanitarian Relief
Children
Education
Health
Languages:
English
Hindi
Punjabi
Taruna Arora Photo 2

Taruna Arora

View page
Taruna Arora Photo 3

Taruna Arora

View page
Taruna Arora Photo 4

Taruna Arora

View page
Taruna Arora Photo 5

Taruna Arora

View page
Taruna Arora Photo 6

Taruna Arora

View page
Taruna Arora Photo 7

Ngm Biopharma Heading Antibody Therapeutic Development And Bioanalytical Assays , Also Owner Of Rst Biotechnology

View page
Position:
Heading antibody development and bioanalytical assays at NGM Biopharmaceuticals, Owner at RST Biotechnology, Editorial board member at Mabs
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
NGM Biopharmaceuticals - South San Francisco since Apr 2012
Heading antibody development and bioanalytical assays
RST Biotechnology since Jan 2012
Owner
Mabs since Jan 2012
Editorial board member
Amgen Inc 2003 - Dec 2011
Principal Scientist , Group leader
Protein Pathways 2002 - 2003
Staff Scientist
Education:
Mayo Graduate School
UCLA
Skills:
Antibody engineering
Hybridoma technologies
Antibody effector functions
External business alliances
Cross-functional Team Leadership
Antibody Lead Generation
Biotherapeutic Leads Development
Immunogenicity models development
Cell Based Assays
High Throughput Screening
Cell line engineering
Protein Expression
Molecular Biology
Structure aided protein design and engineering
Cell biology
Cell signaling
Immunofluorescence
Humanization
Due Diligence
Therapeutics
Immunology
Cell
Antibodies
Assay Development
Cell Signaling
Therapists
Protein Chemistry
Hybridoma
Biotechnology
Functions
Cell Biology

Publications

Us Patents

Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody

View page
US Patent:
8454961, Jun 4, 2013
Filed:
Mar 22, 2012
Appl. No.:
13/427745
Inventors:
Hailing Hsu - Moorpark CA, US
Ian Foltz - Burnaby, CA
Taruna Arora - Thousand Oaks CA, US
Frederick W. Jacobsen - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/18
C07K 16/28
US Classification:
4241431, 4241301, 4241331, 4241411, 5303871, 5303881, 53038822
Abstract:
There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.

Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody

View page
US Patent:
8454962, Jun 4, 2013
Filed:
Mar 22, 2012
Appl. No.:
13/427757
Inventors:
Hailing Hsu - Moorpark CA, US
Ian Foltz - Burnaby, CA
Taruna Arora - Thousand Oaks CA, US
Frederick W. Jacobsen - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/18
C07K 16/28
US Classification:
4241431, 4241301, 4241331, 4241411, 5303871, 5303881, 53038822
Abstract:
There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.

Alpha-4 Beta-7 Heterodimer Specific

View page
US Patent:
20100254975, Oct 7, 2010
Filed:
Mar 16, 2010
Appl. No.:
12/725031
Inventors:
Hailing Hsu - Moorpark CA, US
Ian Foltz - Burnaby, CA
Taruna Arora - Thousand Oaks CA, US
Frederick W. Jacobsen - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/00
C07H 21/04
A61P 1/00
A61P 1/06
C12N 15/63
C12N 5/10
C12P 21/02
US Classification:
4241301, 5303871, 536 2353, 536 2431, 4353201, 435325, 435 696, 435375
Abstract:
There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.

Human Antigen Binding Proteins That Bind Beta-Klotho, Fgf Receptors And Complexes Thereof

View page
US Patent:
20110135657, Jun 9, 2011
Filed:
Dec 3, 2010
Appl. No.:
12/960407
Inventors:
Ian Foltz - Burnaby, CA
Chadwick Terence King - North Vancouver, CA
Yang Li - Mountain View CA, US
Taruna Arora - Thousand Oaks CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 16/00
C07K 16/40
C07K 16/28
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/00
C12P 21/02
A61P 3/10
A61P 3/06
A61P 3/00
A61P 3/04
A61P 9/00
US Classification:
4241581, 5303891, 5303898, 530324, 5303873, 5303881, 4241301, 4241721, 536 2353, 4353201, 435325, 435243, 435 696, 435 692
Abstract:
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

Selective And Potent Peptide Inhibitors Of Kv1.3

View page
US Patent:
20120121591, May 17, 2012
Filed:
Mar 19, 2010
Appl. No.:
13/258454
Inventors:
John K. Sullivan - Newbury Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Colin V. Gegg - Newbury Park CA, US
Edward J. Belouski - Camarillo CA, US
Justin K. Murray - Moorpark CA, US
Hung Nguyen - Camarillo CA, US
Kenneth W. Walker - Newbury Park CA, US
Taruna Arora - Thousand Oaks CA, US
Frederick W. Jacobsen - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Thomas C. Boone - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07K 14/765
C07K 16/00
C07K 14/47
C07K 19/00
A61K 38/16
A61P 25/00
A61P 3/10
A61P 17/06
A61P 29/00
A61P 11/06
A61P 13/12
A61P 19/08
A61K 38/38
A61K 38/17
A61P 37/06
A61P 17/00
A61P 19/02
A61P 37/08
A61P 9/00
A61P 43/00
C07K 14/00
US Classification:
4241341, 530325, 530363, 5303917, 530409, 5303873, 514 213, 514 179, 514 73, 514 186, 514 166, 514 17, 514 154, 514 167, 514 152, 514 212, 4241831
Abstract:
Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.

Carrier Immunoglobulins And Uses Thereof

View page
US Patent:
20120195879, Aug 2, 2012
Filed:
Mar 19, 2010
Appl. No.:
13/258668
Inventors:
Kenneth W. Walker - Newbury Park CA, US
Yue-Sheng Li - Thousand Oaks CA, US
Thomas C. Boone - Newbury Park CA, US
Frederick W. Jacobsen - Newbury Park CA, US
HoSung Min - Bundang-gu, KR
Jane Talvenheimo - Thousand Oaks CA, US
Taruna Arora - Thousand Oaks CA, US
George Doellgast - Asheville NC, US
Janet Doellgast - Asheville NC, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/395
C07H 21/04
C12N 15/63
C07K 16/00
C12P 21/06
C12N 5/16
US Classification:
4241301, 435 696, 435326, 4353201, 5303873, 5303881, 5303891, 5303917, 536 2353
Abstract:
Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

Bispecific Binding Agents

View page
US Patent:
20130164293, Jun 27, 2013
Filed:
Feb 29, 2012
Appl. No.:
13/409019
Inventors:
Monica Florio - Thousand Oaks CA, US
Taruna Arora - Thousand Oaks CA, US
Christopher J. R. Paszty - Ventura CA, US
William G. Richards - Thousand Oaks CA, US
International Classification:
C07K 16/22
US Classification:
4241361, 5303873
Abstract:
The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.

Carrier Immunoglobulins And Uses Thereof

View page
US Patent:
20130189283, Jul 25, 2013
Filed:
Sep 22, 2011
Appl. No.:
13/825547
Inventors:
Kenneth W. Walker - Newbury Park CA, US
Frederick W. Jacobsen - Newbury Park CA, US
Taruna Arora - Thousand Oaks CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
C07K 16/28
C07K 16/18
US Classification:
4241721, 5303891, 53038822, 53038815, 5303917, 536 2353, 4353201, 4352523, 435 696, 43525233, 43525231, 43525234, 43525235, 43525411, 4352542, 43525421, 43525423, 43525422, 4352544, 4352545, 4352543, 435345
Abstract:
Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
Control profile
Taruna Arora from Palo Alto, CA, age ~54 Get Report